Enliven Therapeutics Inc’s recent filing unveils that its CHIEF FINANCIAL OFFICER Hohl Benjamin unloaded Company’s shares for reported $22500.0 on May 03 ’24. In the deal valued at $22.50 per share,1,000 shares were sold. As a result of this transaction, Hohl Benjamin now holds 0 shares worth roughly $0.0.
Then, Lyssikatos Joseph P sold 12,000 shares, generating $214,988 in total proceeds. Upon selling the shares at $17.92, the CHIEF SCIENTIFIC OFFICER now owns 0 shares.
Before that, Hohl Benjamin sold 3,250 shares. Enliven Therapeutics Inc shares valued at $55,165 were divested by the CHIEF FINANCIAL OFFICER at a price of $16.97 per share. As a result of the transaction, Hohl Benjamin now holds 0 shares, worth roughly $0.0.
Mizuho initiated its Enliven Therapeutics Inc [ELVN] rating to a Buy in a research note published on April 09, 2024; the price target was $34. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late March with a ‘”a Buy”‘ rating.
Price Performance Review of ELVN
On Tuesday, Enliven Therapeutics Inc [NASDAQ:ELVN] saw its stock jump 7.77% to $24.70. Over the last five days, the stock has gained 42.04%. Enliven Therapeutics Inc shares have risen nearly 78.47% since the year began. Nevertheless, the stocks have risen 25.76% over the past one year. While a 52-week high of $26.00 was reached on 04/11/24, a 52-week low of $9.80 was recorded on 03/15/24. SMA at 50 days reached $17.67, while 200 days put it at $15.14. A total of 0.61 million shares were traded, compared to the trading of 0.31 million shares in the previous session.
Levels Of Support And Resistance For ELVN Stock
The 24-hour chart illustrates a support level at 23.41, which if violated will result in even more drops to 22.13. On the upside, there is a resistance level at 25.49. A further resistance level may holdings at 26.29. The Relative Strength Index (RSI) on the 14-day chart is 71.37, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 4.43, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 3.32%. Stochastics %K at 96.86% indicates the stock is a selling.
